Clinical trials: Obesity Overweight
Obesity
The Effect of SHR20004（Noiiglutide ） on Body Weight in Obese Subjects Without Diabetes
The study is being conducted to assess the efficacy and safety of SHR20004 on body weight in obese subjects without diabetes.
- Trial name
- NCT04799327
- Testing
- SHR20004
- Where
- 2 sites in China
- Volunteers
- 254 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Healthy
Bioequivalence Study Comparing Naltrexone SR/Bupropion SR Trilayer Tablets From Two Manufacturers
This is a Phase 1, open-label, randomized, single-dose, 2-way crossover study in healthy adult subjects to assess the bioequivalence of naltrexone SR/bupropion SR combination trilayer tablets prepared at two different…
- Trial name
- NCT02259179
- Testing
- Reference naltrexone 8 mg SR/bupropion 90 mg SR combination trilayer tablets (2 tablets), Test naltrexone 8 mg SR/bupropion 90 mg SR combination trilayer tablets (2 tablets)
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Orexigen Therapeutics, Inc
Obesity & Overweight, Mobility Disability
Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss
The primary objective of this study is to assess the effect of enobosarm on total body weight
- Conditions
- Obesity & Overweight, Mobility Disability, HOMA-IR
- Trial name
- PLATEAU (NCT07446998)
- Testing
- Enobosarm, Semaglutide (Wegovy) weekly injection
- Where
- 13 sites in United States
- Volunteers
- 239 people
- Sponsor
- Veru Inc.
Overweight and Obesity
Evaluate the Safety and Efficacy of HDM1002 Tablets in Overweight and Obese Adults
It is a multicenter, randomized, double-blind, placebo-controlled phase II clinical trial to evaluate the safety and efficacy of HDM1002 tablets in overweight and obese adults.
- Trial name
- NCT06500299
- Testing
- HDM1002 100 mg QD, HDM1002 200 mg QD 12weeks, HDM1002 400 mg QD 12weeks
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Obesity
A Phase 2 Study Evaluating the Co-Administration of Bremelanotide With Tirzepatide for the Treatment of Obesity
This is a prospective, randomized, double-blind, placebo-controlled study designed to assess the safety and efficacy of bremelanotide (BMT) used in combination with tirzepatide therapy in the treatment of obesity in subjects with…
- Trial name
- BMT-801 (NCT06565611)
- Testing
- bremelanotide, tirzepatide
- Where
- 4 sites in United States
- Volunteers
- 108 people
- Sponsor
- Palatin Technologies, Inc
Type 2 Diabetes Mellitus
Study of Multiple Oral Doses of PF-07081532 in Adult Participants With Type 2 Diabetes Mellitus
This is a Phase 1, randomized, placebo-controlled, double-blind (investigator- and participant-blinded), sponsor-open study of PF-07081532.
- Trial name
- NCT05158244
- Testing
- PF-07081532
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Pfizer
Overweight , Obesity
Phase 2 Study to Evaluate the Efficacy and Safety of MWN109 Injection in Non-Diabetic Participants With Overweight
This study is a multicenter, randomized, double-blind, placebo-controlled phase II study conducted in China. It aims to evaluate the efficacy and safety of MWN109 injection in non-diabetic overweight or obese participants.
- Trial name
- NCT07791537
- Testing
- MWN109 1, MWN109 2, MWN109 3
- Where
- China
- Volunteers
- 125 people
- Sponsor
- Shanghai Minwei Biotechnology Co., Ltd
Obesity
Use of the Incisionless Operating Platform as a Primary Treatment for Obesity vs. Diet-Exercise Alone
This study is a multi-center, open/unblended study (3:1Treatment: Control) to evaluate the safety and effectiveness of the g-Cath EZ Suture Anchor Delivery Catheter as an early weight loss intervention compared to a diet and…
- Trial name
- MILEPOST (NCT01843231)
- Testing
- g-CathTM EZ Suture Anchor Delivery Catheter, Diet and Exercise Control Group
- Where
- 3 sites in Austria, Netherlands and 1 more
- Volunteers
- 40 people
- Sponsor
- USGI Medical
Obesity
Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscle Health)
The purpose of this clinical study is to look into how study medicines CagriSema (cagrilintide and semaglutide), cagrilintide, and semaglutide affects muscle health in people with excess body weight and slightly higher than…
- Trial name
- RASMUS (NCT07527195)
- Testing
- Cagrilintide, Semaglutide
- Where
- Denmark
- Volunteers
- 100 people
- Sponsor
- Novo Nordisk A/S
Hypertension
Study of the Efficacy and Safety of Aliskiren HCTZ vs Ramipril in Obese Patients (BMI ≥ 30) With Stage 2 Hypertension
Study to Evaluate the Efficacy and Safety of Aliskiren Hydrochlorothiazide (HCTZ) vs Ramipril in Obese patients (BMI ≥ 30) with Stage 2 Hypertension
- Trial name
- ATTAIN (NCT00772577)
- Testing
- Aliskiren Hydrochlorothiazide, Ramipril
- Where
- 6 sites in United States
- Volunteers
- 386 people
- Sponsor
- Novartis
Obesity
A Research Study to Look at How CagriSema Influences Food Intake, Appetite and Emptying of the Stomach in People With Excess Body Weight
This research study tests if CagriSema influences food intake, appetite and emptying of the stomach in people with excess body weight.
- Trial name
- NCT06207877
- Testing
- Cagrilintide, Semaglutide
- Where
- Germany
- Volunteers
- 62 people
- Sponsor
- Novo Nordisk A/S
Obesity
Multiple Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of THDBH120 in Chinese Patients With Obesity
The aim of this trial is to investigate the safety, tolerability, pharmacokinetics, and efficacy of THDBH120 injection in participants with obesity. This study includes three multiple-ascending dose cohorts.
- Trial name
- NCT06951945
- Testing
- THDBH120 injection
- Where
- 2 sites in China
- Volunteers
- 36 people
- Sponsor
- Tonghua Dongbao Pharmaceutical Co.,Ltd
Obesity, Metabolic Syndrome
Effects of Telemonitoring Service for Obesity Care
A randomized, open, parallel, multi-center trial to evaluate weight loss efficacy of Smart Care Service in obese patients with metabolic syndrome.
- Trial name
- Smart-OB (NCT01344811)
- Testing
- Telemonitoring, control group
- Where
- 2 sites in South Korea
- Volunteers
- 661 people
- Sponsor
- Chang Hee, Lee
Obesity, Roux-en-Y Gastric Bypass
A Post-market, Observational Registry With the easyEndoTM Universal Linear Cutting Stapler in Laparoscopic Bariatric Surgery
The purpose of this observational registry is to evaluate the safety and performance of the easyEndoTM Universal Linear Cutting Stapler and reloads from Ezisurg Medical when used to create anastomoses during laparoscopic…
- Conditions
- Obesity, Roux-en-Y Gastric Bypass, Gastrectomy, Mini Gastric Bypass
- Trial name
- STAP-Delta (NCT04422236)
- Testing
- easyEndoTM Universal Linear Cutting Stapler and reloads (Ezisurg Medical)
- Where
- Belgium
- Volunteers
- 200 people
- Sponsor
- Duomed
Overweight, Healthy Volunteers
A Research Study Looking at the Safety of Multiple Doses of ZP8396 and How it Works in the Body of Healthy Participants
The trial is a single-centre, randomised and double-blind within cohorts, placebo-controlled, sequential multiple ascending dose trial in normal weight and overweight but otherwise healthy subjects randomised to subcutaneous…
- Conditions
- Overweight, Healthy Volunteers, Obese
- Trial name
- NCT05613387
- Testing
- ZP8396
- Where
- Germany
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Zealand Pharma
Obesity
A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes
The purpose of this study is to investigate the efficacy and safety of eloralintide and tirzepatide coformulation (EloraTZP) compared with tirzepatide, eloralintide and placebo for body weight reduction in participants with…
- Trial name
- AMPLIFY-1 (NCT07881432)
- Testing
- eloralintide and tirzepatide, Eloralintide, Tirzepatide
- Where
- 155 sites in United States, Argentina and 7 more
- Volunteers
- 2,115 people
- Sponsor
- Eli Lilly and Company
Obesity
Study to Evaluate ARD-101 in Adults With Obesity
The purpose of this study is to evaluate safety and efficacy of twice-daily ARD-101 in obese subjects with a body mass index (BMI) of 30-45 kg/m2.
- Trial name
- NCT05121441
- Testing
- ARD-101
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Aardvark Therapeutics, Inc.
Overweight, Type 2 Diabetes
Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)
The main purpose of this study is to investigate efficacy and safety of three doses of petrelintide versus placebo in participants with overweight or obesity and type 2 diabetes.
- Conditions
- Overweight, Type 2 Diabetes, Obesity
- Trial name
- NCT06926842
- Testing
- Petrelintide
- Where
- 48 sites in United States
- Volunteers
- 221 people
- Sponsor
- Zealand Pharma
Obesity & Overweight, Type 2 Diabetes
A Food-Effect Study of CX11 in Healthy Participants
This study is to evaluate the food effect (FE) on the PK of 200 mg CX11 in healthy participants
- Trial name
- NCT07349381
- Testing
- CX11 (VCT220)
- Where
- China
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Vincentage Pharma Co., Ltd
Type 2 Diabetes Mellitus (T2DM), Obesity and Overweight
CK-0045 Proof-of-concept Study in Participants With Overweight / Obesity and Type 2 Diabetes
The goal of this clinical trial is to learn if treatment with CK-0045 improves blood sugar control after a meal in participants with type 2 diabetes mellitus (T2DM) and overweight/obesity.
- Trial name
- NCT06611930
- Testing
- CK-0045
- Where
- 2 sites in Germany
- Volunteers
- 90 people
- Sponsor
- Cytoki Pharma